Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > PBLA Panbela Therapeutics > Company Executives
PBLA Panbela Therapeutics
NamePositionSalaryService DateEducationAgeGenderUpdated
Dr. Jennifer K Simpson, PhDDirector, President and Chief Executive Officer1.20M----53female04/29/2022
Ms. Susan HorvathVice President, Finance, Principal Accounting Officer, Chief Financial Officer, Secretary and Treasurer557.08K----62female03/24/2022
Mr. Jeffrey S. MathiesenVice Chairman of the Board and Lead Independent Director128.16K----61male04/29/2022
Dr. Michael T. Cullen, M.B.A.,M.D.Chairman of the Board93.78K----76male04/29/2022
Dr. Suzanne Gagnon, M.D.Director------65female04/29/2022
Mr. Arthur J. Fratamico, R.Ph.Independent Director98.16K----56male04/29/2022
Mr. Paul W. SchafferIndependent Director109.41K----79male04/29/2022
Mr. D. Robert SchemelIndependent Director106.91K----66male04/29/2022
Company Overview More
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.
CEO: Dr. Jennifer K Simpson, PhD
Market: NASDAQ
Listing Date: 08/28/2020
Futu Hot List
SymbolLatest price%Chg